![]() | |
Names | |
---|---|
IUPAC name
(6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
Other names
Antibiotic E 1077 | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
KEGG |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C20H25FN8O6S2 | |
Molar mass | 556.59 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Cefluprenam is a fourth generation cephalosporin.[1] It was patented in 2008 by now defunct Cubist Pharmaceuticals.[2] A 1997 clinical trial illustrated that Cefluprenam is highly effective against bacterial pneumonia.[3]
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |